Other equities research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 11th. TheStreet lowered Trade Desk from a “b-” rating to a “c-” rating in a research note on Thursday, May 9th. ValuEngine lowered Yext from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 10th. Raymond James began coverage on Adverum Biotechnologies in a research note on Thursday, June 13th. They issued a “market perform” rating for the company. Finally, Chardan Capital restated a “buy” rating and issued a $150.00 price objective (up from $145.00) on shares of Regenxbio in a research note on Tuesday, June 18th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Regenxbio currently has a consensus rating of “Hold” and a consensus price target of $81.53.
Shares of RGNX opened at $47.48 on Thursday. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of 19.95 and a beta of 0.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.21 and a current ratio of 14.21. The company’s fifty day moving average is $48.19. Regenxbio has a 1-year low of $38.56 and a 1-year high of $83.45.
Regenxbio (NASDAQ:RGNX) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.04). The company had revenue of $0.88 million for the quarter. Regenxbio had a negative net margin of 41.99% and a negative return on equity of 9.90%. Research analysts expect that Regenxbio will post -2.46 earnings per share for the current fiscal year.
In other news, insider Olivier Danos sold 2,000 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $52.66, for a total value of $105,320.00. Following the completion of the sale, the insider now directly owns 8,500 shares in the company, valued at approximately $447,610. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Curran Simpson sold 18,000 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $50.00, for a total value of $900,000.00. Following the completion of the sale, the senior vice president now owns 57,500 shares of the company’s stock, valued at $2,875,000. The disclosure for this sale can be found here. Insiders sold a total of 75,000 shares of company stock valued at $3,725,970 over the last 90 days. 13.80% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of RGNX. Norges Bank purchased a new stake in Regenxbio in the 4th quarter worth $10,798,000. Dimensional Fund Advisors LP increased its stake in Regenxbio by 157.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 321,713 shares of the biotechnology company’s stock worth $13,496,000 after buying an additional 196,944 shares in the last quarter. Perceptive Advisors LLC increased its stake in Regenxbio by 37.2% in the 4th quarter. Perceptive Advisors LLC now owns 645,726 shares of the biotechnology company’s stock worth $26,894,000 after buying an additional 175,054 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Regenxbio by 47.7% in the 4th quarter. Bank of New York Mellon Corp now owns 530,908 shares of the biotechnology company’s stock worth $22,272,000 after buying an additional 171,493 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in Regenxbio by 1,746.7% in the 1st quarter. SG Americas Securities LLC now owns 179,279 shares of the biotechnology company’s stock worth $10,274,000 after buying an additional 169,571 shares in the last quarter. Hedge funds and other institutional investors own 81.48% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Read More: Why is the ROA ratio important?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.